Table 3 Radiotherapic treatment dosimetry and delivery
| Â | Median (IQR) | Range |
|---|---|---|
NCI | 1.29 (1.19–1.52) | 1.12–3.10 |
HI | 1.16 (1.13–1.18) | 1.06–1.25 |
Median PTV isodose prescription % | 86.0 (85.0–88.5) | 82.0–94.0 |
Total number of beams | 180 (107–213) | 56–325 |
Monitor Units | 17,524 (13949–22,123) | 7519–44,385 |
Volume of lesion (mm3) | 88,098 (63835–108,617) | 32,256–238,832 |
Homolateral lung V30% | 2.3 (0.25–3.15) | 0.0–9.4 |
Contralateral lung V5% | 1.15 (0.00–3.65) | 0.00–17.00 |
Heart V5% (right breast cancer) | 0.2 (0.0–3.3) | 0.0–5.2 |
Heart V5% (left breast cancer) | 14.0 (12.1–29.7) | 7.4–33.0 |
Thyroid Dmax (Gy) | 0.26 (0.14–0.44) | 0.09–1.00 |
Skin Dmax (Gy) | 29.46 (27.97–30.33) | 21.04–32.00 |
Homolateral breast V50% | 28.7 (20.0–32.6) | 13.0–57.0 |
Homolateral breast V100% | 75.0 (52.5–104.0) | 8.0–202.0 |
Contralateral breast D100% (Gy) | 0.09 (0.03–0.12) | 0.00–0.25 |
PTV Dmin (Gy) | 26.2 (24.7–27.6) | 22.3–29.3 |
PTV V90% | 100 (98.7–100) | 92.0–100 |